Drug Profile
Research programme: skin disorders therapy - LEO Pharma/SWITCH Biotech
Alternative Names: Atopic dermatitis therapy research programme - LEO Pharma/SWITCH Biotech; Psoriasis therapy research programme - LEO Pharma/SWITCH Biotech; Skin disorders therapy research programme - LEO Pharma/SWITCH BiotechLatest Information Update: 02 Jun 2005
Price :
$50
*
At a glance
- Originator LEO Pharma; SWITCH Biotech (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Psoriasis
Most Recent Events
- 01 Mar 2005 Discontinued - Preclinical for Atopic dermatitis in Denmark (unspecified route)
- 01 Mar 2005 Discontinued - Preclinical for Atopic dermatitis in Germany (unspecified route)
- 01 Mar 2005 Discontinued - Preclinical for Psoriasis in Denmark (unspecified route)